CHEK:NSD-Check-Cap Ltd (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 1.12

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

0.98M

Avg Analyst Target

USD 3.00 (+167.86%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a disposable system attached to the patient's back via biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis and report generation. The company was founded in 2004 and is based in Isfiya, Israel.

Company Website : http://www.check-cap.com

Address : Check-Cap Building, Isfiya, Israel, 30090

Employees : 65

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.21

52 Week High : 2.46

Short Ratio : 0.84

52 Week Low : 0.24

Shorted Shares : 4,243,136

200 Day Moving Average : 1.58

Shorted Shares Previous Month : 3,832,236

50 Day Moving Average : 1.39

Shares Held By Insiders : 7.83%

Short Percentage : 6.00%

Shares Held by Institutions : 3.93%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

N/A

 USD72.34B 115.77 63.37
IDXX IDEXX Laboratories, Inc

N/A

 USD59.16B 89.27 66.74
DXCM DexCom, Inc

N/A

 USD44.55B 88.51 111.46
EXAS Exact Sciences Corporation

N/A

 USD20.23B N/A N/A
ICLR ICON Public Limited Company

N/A

 USD17.35B 34.33 30.78
GH Guardant Health, Inc

N/A

 USD12.06B N/A N/A
OZON Ozon Holdings PLC

N/A

 USD11.24B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

 USD10.70B 50.52 25.79
NTRA Natera, Inc

N/A

 USD10.03B N/A N/A
SYNH Syneos Health, Inc

N/A

 USD9.14B 47.18 22.93

ETFs Containing CHEK

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 143.48% 98% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 143.48% 98% A+ 97% A+
Trailing 12 Months  
Capital Gain 88.24% 73% C 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 88.24% 73% C 80% B-
Trailing 5 Years  
Capital Gain -92.59% 16% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -92.59% 16% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -39.66% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.66% 3% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 63.73% 49% F 28% F
Risk Adjusted Return -62.23% 8% F 4% F
Market Capitalization 0.08B 21% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.20 89% B+ 92% A-
Price/Book Ratio 2.46 82% B- 54% F
Price / Cash Flow Ratio -6.02 62% D- 67% D+
EV/EBITDA 0.23 87% B+ 94% A
Management Effectiveness  
Return on Equity -70.33% 22% F 24% F
Return on Invested Capital -123.23% 11% F 5% F
Return on Assets -37.33% 11% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.84 90% A- 75% C
Short Percent 6.50% 45% F 30% F
Beta 0.21 94% A 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.